Trial Profile
A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2019
Price :
$35
*
At a glance
- Drugs Etravirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 02 Aug 2019 Status changed from recruiting to completed(Global end date : 2008-02-27).
- 29 Aug 2011 New trial record